Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102401 | 0.93 | GLS (0.39) | MEN1POLBKMT2A | |
| SCHEMBL13102432 | 0.91 | RXFP1 (0.41) | MEN1POLBKMT2AGPR139NPSR1 | |
| SCHEMBL13102285 | 0.90 | NPSR1 (0.44) | MEN1POLBKMT2ANPSR1ALDH1A1 | |
| SCHEMBL13102493 | 0.89 | ALDH1A1 (0.40) | MEN1POLBKMT2AGPR139NPSR1 | |
| SCHEMBL13102005 | 0.86 | KDM4E (0.43) | MEN1KMT2AGPR139 | |
| SCHEMBL13101677 | 0.86 | NPSR1 (0.51) | MEN1POLBKMT2ANPSR1ALDH1A1 | |
| SCHEMBL13102398 | 0.86 | RAB9A (0.43) | MEN1POLBKMT2AGPR139ALDH1A1 | |
| SCHEMBL13101991 | 0.86 | RORC (0.41) | MEN1POLBKMT2AGPR139ALDH1A1 | |
| SCHEMBL13101990 | 0.84 | THRB (0.43) | MEN1POLBKMT2AGPR139RXFP1 | |
| SCHEMBL13102415 | 0.84 | P2RY14 (0.41) | GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | MEN1 781/4885POLB 2705/4885KMT2A 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.